

Raija Silvennoinen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1887453/publications.pdf>

Version: 2024-02-01

32
papers

360
citations

759233

12
h-index

839539

18
g-index

32
all docs

32
docs citations

32
times ranked

579
citing authors

#	ARTICLE	IF	CITATIONS
1	Prognostic significance of esterase gene expression in multiple myeloma. <i>British Journal of Cancer</i> , 2021, 124, 1428-1436.	6.4	18
2	Aminopeptidase Expression in Multiple Myeloma Associates with Disease Progression and Sensitivity to Melflufen. <i>Cancers</i> , 2021, 13, 1527.	3.7	29
3	Long-term outcome after allogeneic stem cell transplantation in multiple myeloma. <i>Annals of Hematology</i> , 2021, 100, 1553-1567.	1.8	6
4	Autograft cellular composition and outcome in myeloma patients: Results of the prospective multicenter GOA study. <i>Transfusion</i> , 2021, 61, 1830-1844.	1.6	11
5	Next generation proteomics with drug sensitivity screening identifies sub-clones informing therapeutic and drug development strategies for multiple myeloma patients. <i>Scientific Reports</i> , 2021, 11, 12866.	3.3	8
6	Patient Preferences for Multiple Myeloma Treatments: A Multinational Qualitative Study. <i>Frontiers in Medicine</i> , 2021, 8, 686165.	2.6	21
7	S100 Calcium Binding Protein Family Members Associate With Poor Patient Outcome and Response to Proteasome Inhibition in Multiple Myeloma. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 723016.	3.7	5
8	A candid view of CANDOR. <i>Lancet, The</i> , 2020, 396, 147-148.	13.7	1
9	CD34+ cell mobilization, blood graft composition, and posttransplant recovery in myeloma patients compared to non-Hodgkin's lymphoma patients: results of the prospective multicenter GOA study. <i>Transfusion</i> , 2020, 60, 1519-1528.	1.6	9
10	RVD induction and autologous stem cell transplantation followed by lenalidomide maintenance in newly diagnosed multiple myeloma: a phase 2 study of the Finnish Myeloma Group. <i>Annals of Hematology</i> , 2019, 98, 2781-2792.	1.8	12
11	Blood graft composition and post-transplant recovery in myeloma patients mobilized with plerixafor: a prospective multicenter study. <i>Leukemia and Lymphoma</i> , 2019, 60, 453-461.	1.3	8
12	Real-world treatment outcomes in multiple myeloma: Multicenter registry results from Finland 2009-2013. <i>PLoS ONE</i> , 2018, 13, e0208507.	2.5	25
13	Impact of lenalidomide-based induction therapy on the mobilization of CD34 ⁺ cells, blood graft cellular composition, and post-transplant recovery in myeloma patients: a prospective multicenter study. <i>Transfusion</i> , 2017, 57, 2366-2372.	1.6	7
14	Increased Mutational Burden and Alterations to DNA Damage Repair Genes are Associated With Poor Prognosis and Sensitivity to PI3K-mTOR Inhibitors in Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, e2.	0.4	0
15	Identification of precision treatment strategies for relapsed/refractory multiple myeloma by functional drug sensitivity testing. <i>Oncotarget</i> , 2017, 8, 56338-56350.	1.8	35
16	Blood graft cellular composition and posttransplant outcomes in myeloma patients mobilized with or without low-dose cyclophosphamide: a randomized comparison. <i>Transfusion</i> , 2016, 56, 1394-1401.	1.6	14
17	Cost analysis of a randomized stem cell mobilization study in multiple myeloma. <i>Annals of Hematology</i> , 2016, 95, 1653-1659.	1.8	9
18	Invasive pneumococcal disease in patients with haematological malignancies before routine use of conjugate vaccines in Finland. <i>Infectious Diseases</i> , 2016, 48, 399-402.	2.8	12

#	ARTICLE	IF	CITATIONS
19	Blood graft cellular composition and posttransplant recovery in non-Hodgkin's lymphoma patients mobilized with or without plerixafor: a prospective comparison. <i>Transfusion</i> , 2015, 55, 2358-2368.	1.6	20
20	A Randomized Comparison of Low-Dose Cyclophosphamide + G-CSF Versus G-CSF Alone Mobilization after Lenalidomide-Bortezomib-Dexamethasone (RVD) Induction in Multiple Myeloma. <i>Blood</i> , 2014, 124, 847-847.	1.4	0
21	Integration of Ex Vivo Drug Testing and in-Depth Molecular Profiling Reveals Oncogenic Signaling Pathways and Novel Therapeutic Strategies for Multiple Myeloma. <i>Blood</i> , 2014, 124, 2046-2046.	1.4	3
22	Identification of Dual PI3K/mTOR and BCL2 Inhibitors for the Treatment of High Risk Multiple Myeloma. <i>Blood</i> , 2014, 124, 646-646.	1.4	0
23	Landscape of Driver Lesions in Multiple Myeloma and Consequences for Targeted Drug Response. <i>Blood</i> , 2014, 124, 3351-3351.	1.4	0
24	CD34+ cell subclasses and lymphocyte subsets in blood grafts collected after various mobilization methods in myeloma patients. <i>Transfusion</i> , 2013, 53, 1024-1032.	1.6	29
25	Assessment of molecular remission rate after bortezomib plus dexamethasone induction treatment and autologous stem cell transplantation in newly diagnosed multiple myeloma patients. <i>British Journal of Haematology</i> , 2013, 160, 561-564.	2.5	14
26	High cut-off hemodialysis and bortezomib-based therapy to rescue kidneys in myeloma-dependent cast nephropathy. <i>American Journal of Hematology</i> , 2012, 87, 640-640.	4.1	14
27	Comparison of Blood Graft Cellular Content in Myeloma (MM) Patients and Non-Hodgkin Lymphoma (NHL) Patients Mobilized with Chemotherapy Plus G-CSF with or without Plerixafor. <i>Blood</i> , 2012, 120, 4414-4414.	1.4	0
28	Improved Response Rate with Bortezomib Consolidation After High Dose Melphalan: First Results of a Nordic Myeloma Study Group Randomized Phase III Trial. <i>Blood</i> , 2009, 114, 530-530.	1.4	19
29	Long-term outcome of intensive chemotherapy for adults with de novo acute myeloid leukaemia (AML): the nationwide AML-92 study by the Finnish Leukaemia Group. <i>European Journal of Haematology</i> , 2007, 78, 477-486.	2.2	19
30	Pharmacokinetics of Chlorambucil in Patients with Chronic Lymphocytic Leukaemia: Comparison of Different Days, Cycles and Doses. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2000, 87, 223-228.	0.0	3
31	Detoxification of an Alkylating Drug, N,N-Bis(2-chloroethyl)-p-aminophenylbutyric Acid (Chlorambucil), in Human Gastric Juice and Saliva. <i>Chemical Research in Toxicology</i> , 1998, 11, 91-93.	3.3	8
32	Efficacy of conventional-dose cytarabine, idarubicin and thioguanine (IAT) versus intermediate-dose cytarabine and idarubicin (IdAra-Cd) in the induction treatment of AML: long-term results of the prospective randomized nationwide AML-2003 study by the Finnish Leukemia Group. <i>European Journal of Haematology</i> , 0, . .	2.2	1